Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07643597

Volume Removal Intolerance During Net Ultrafiltration in Acute Kidney Injury Patients

Acute kidney injury (AKI) is common in critically ill patients and is frequently associated with fluid overload, which can worsen clinical outcomes. Continuous renal replacement therapy (CRRT) allows fluid removal through net ultrafiltration (UFNET), but some patients develop hemodynamic instability or signs of poor tissue perfusion during this process.

The purpose of this prospective observational study is to evaluate tolerance to net ultrafiltration in critically ill patients with AKI receiving CRRT. The study will assess clinical, hemodynamic, ultrasound, perfusion, and biochemical parameters before and during fluid removal to identify factors associated with ultrafiltration intolerance.

The investigators hypothesize that alterations in hemodynamic, perfusion, and congestion-related parameters can identify patients at increased risk of ultrafiltration intolerance before the development of overt hypotension. The results may help improve individualized fluid removal strategies and optimize the safety of CRRT in critically ill patients.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Fluid overload is a frequent and clinically relevant complication in critically ill patients with acute kidney injury (AKI). In this setting, continuous renal replacement therapy (CRRT) is frequently used not only for solute control but also as a strategy for controlled fluid removal through net ultrafiltration (UFNET). Although UFNET is central to de-resuscitation, the individual tolerance to fluid removal is highly variable and is not fully captured by blood pressure monitoring alone.

The concept of ultrafiltration intolerance remains poorly standardized. In clinical practice, intolerance is often recognized only after overt hemodynamic instability occurs, such as hypotension, escalation of vasoactive support, or interruption of fluid removal. However, reductions in cardiac output, impaired tissue perfusion, or worsening venous congestion may precede overt hypotension. Therefore, a multiparametric assessment may allow earlier identification of patients at risk.

This is a prospective, observational, analytical study in critically ill adult patients with AKI receiving CRRT with prescribed UFNET. The study does not assign or modify therapeutic interventions. CRRT modality, anticoagulation strategy, UFNET prescription, vasopressor management, fluid administration, and all other clinical decisions will remain under the responsibility of the treating clinical team according to routine care.

The study will characterize the physiological response to UFNET using a structured multiparametric monitoring approach. Recorded domains will include conventional macrohemodynamic variables, vasoactive support, selected advanced hemodynamic variables when available, focused cardiac ultrasound, venous congestion assessment, peripheral perfusion parameters, fluid balance variables, and selected biochemical markers. Functional hemodynamic maneuvers may be performed when feasible and clinically safe.

Data will be collected prospectively using a standardized case report form. Variables will be recorded at predefined time points before and during the early phase of UFNET, with additional off-schedule recordings if clinical signs compatible with intolerance occur. Source data will be obtained from the electronic or paper medical record, bedside monitoring systems, CRRT prescription and treatment records, laboratory results, and ultrasound assessments performed as part of clinical evaluation.

A data dictionary will define each variable, including its source, units, coding, and expected physiological range when applicable. Data quality procedures will include review of completeness, range checks, consistency checks between related variables, and verification of clinically implausible values against source records. The research team will periodically review entered data to identify missing, inconsistent, or out-of-range values.

Data will be anonymized before analysis. No directly identifiable patient information will be stored in the final analytical database. Access to the study database will be restricted to authorized study investigators. Data will be stored using password-protected institutional or investigator-controlled systems according to local confidentiality and ethical requirements.

The planned sample size is 128 participants, including an estimated analytical sample of 116 participants and an approximate 10% over-recruitment to account for incomplete data, missing assessments, or inability to definitively adjudicate the outcome. The sample size was based on an analytical case-control approach aimed at identifying factors associated with ultrafiltration intolerance.

Missing data will be evaluated before statistical analysis. Variables with substantial missingness may be excluded from inferential analyses. For variables with acceptable levels of missingness, available-case analysis will be performed. The extent and pattern of missing data will be reported.

Statistical analysis will include descriptive statistics, comparison between patients who develop ultrafiltration intolerance and those who do not, and exploratory modeling to identify factors independently associated with intolerance. Continuous variables will be summarized using median and interquartile range or mean and standard deviation, as appropriate. Categorical variables will be summarized as frequencies and percentages. Group comparisons will be performed using appropriate parametric or non-parametric tests according to data distribution. Multivariable logistic regression may be used to explore independent predictors, with covariate selection based on clinical relevance and number of events.

The overall objective of this study is to improve the characterization of ultrafiltration intolerance during CRRT and to generate evidence that may support individualized, physiology-guided fluid removal strategies in critically ill patients with AKI.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • Admission to an Intensive Care Unit
  • Acute kidney injury according to KDIGO criteria
  • Prescription of continuous renal replacement therapy (CRRT) with net ultrafiltration
  • Clinical stability considered sufficient to initiate net ultrafiltration according to the treating clinical team

Exclusion criteria

  • Chronic kidney replacement therapy prior to ICU admission
  • Pregnancy
  • Limitation of therapeutic effort or goals-of-care decisions at admission or during the observation period
  • Inability to perform hemodynamic or perfusion assessment
  • Extracorporeal membrane oxygenation (ECMO)
  • Refusal to participate in the study

Treatment and study plan

Primary outcomes

  1. Development of Ultrafiltration Intolerance

    Time frame: From UFNET initiation (T0) to 24 hours after initiation of net ultrafiltration

    Proportion of patients who develop ultrafiltration intolerance according to the protocol-defined composite criteria, including hypotension, increased vasopressor requirements, worsening peripheral perfusion, tissue hypoperfusion, or reduction/interruption of ultrafiltration due to instability.

Secondary outcomes

  1. Incidence of Ultrafiltration Intolerance

    Time frame: From UFNET initiation (T0) to 24 hours.

    Percentage of participants who develop ultrafiltration intolerance during the observation period.

  2. Net Ultrafiltration Rate (mL/kg/h)

    Time frame: From UFNET initiation (T0) to 24 hours.

    Prescribed and achieved net ultrafiltration rate during continuous renal replacement therapy.

  3. Time to First Ultrafiltration Intolerance Event (hours)

    Time frame: From UFNET initiation to 24 hours.

    Time from UFNET initiation to the first occurrence of ultrafiltration intolerance.

  4. Severity Category of Ultrafiltration Intolerance

    Time frame: From UFNET initiation to 24 hours.

    Proportion of participants classified as having mild, moderate, or severe ultrafiltration intolerance according to protocol-defined criteria. Higher categories indicate greater severity of intolerance.

  5. Agreement Between Hypotension-Based and Hypoperfusion-Based Definitions of Ultrafiltration Intolerance

    Time frame: From UFNET initiation to 24 hours.

    Agreement between intolerance defined by hypotension criteria and intolerance defined by tissue hypoperfusion criteria, assessed using Cohen's kappa coefficient.

  6. Cumulative Fluid Balance (mL)

    Time frame: 24 hours after UFNET initiation

    Cumulative fluid balance achieved during the first 24 hours following UFNET initiation.

  7. Achieved Net Ultrafiltration Volume (mL)

    Time frame: 24 hours after UFNET initiation

    Total net ultrafiltration volume achieved during the observation period.

  8. Proportion of Participants Achieving Renal Recovery

    Time frame: Up to 90 days after UFNET initiation

    Percentage of participants who recover kidney function sufficiently to discontinue kidney replacement therapy according to the treating clinical team.

  9. Ventilator-Free Days

    Time frame: Up to 28 days after UFNET initiation

    Number of days alive and free from invasive mechanical ventilation.

  10. Intensive Care Unit Mortality

    Time frame: From UFNET initiation up to 90 days or ICU discharge, whichever occurs first

    Percentage of participants who die during intensive care unit admission.

  11. Hospital Mortality

    Time frame: From UFNET initiation until hospital discharge, assessed up to 180 days

    Percentage of participants who die during hospital admission.

Study contacts

Contact information is provided by the study sponsor or research team.

Cristian Pedreros-Rosales, MD

CONTACT

[email protected]

Gonzalo Ramírez-Guerrero, MD

CONTACT

[email protected]

+56981746173

Sponsors and collaborators

Lead sponsor

Hospital Las Higueras

Other

Registry information

Acronym: VINKO

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jun 11, 2026
Registry last updated
Jul 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.